Cardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction
| Parent link: | Biomedicines Vol. 11, iss. 3.— 2023.— [714, 15 p.] |
|---|---|
| Համատեղ հեղինակ: | |
| Այլ հեղինակներ: | , , , , , , , , , , , , , |
| Ամփոփում: | Title screen Activation of c-Jun N-terminal kinases (JNKs) is involved in myocardial injury, left ventricular remodeling (LV), and heart failure (HF) after myocardial infarction (MI). The aim of this research was to evaluate the effects of a selective JNK inhibitor, 11H-indeno [1,2-b]quinoxalin-11-one oxime (IQ-1), on myocardial injury and acute myocardial ischemia/reperfusion (I/R) in adult male Wistar rats. Intraperitoneal administration of IQ-1 (25 mg/kg daily for 5 days) resulted in a significant decrease in myocardial infarct size on day 5 after MI. On day 60 after MI, a significant (2.6-fold) decrease in LV scar size, a 2.2-fold decrease in the size of the LV cavity, a 2.9-fold decrease in the area of mature connective tissue, and a 1.7-fold decrease in connective tissue in the interventricular septum were observed compared with the control group. The improved contractile function of the heart resulted in a significant (33%) increase in stroke size, a 40% increase in cardiac output, a 12% increase in LV systolic pressure, a 28% increase in the LV maximum rate of pressure rise, a 45% increase in the LV maximum rate of pressure drop, a 29% increase in the contractility index, a 14% increase in aortic pressure, a 2.7-fold decrease in LV end-diastolic pressure, and a 4.2-fold decrease in LV minimum pressure. We conclude that IQ-1 has cardioprotective activity and reduces the severity of HF after MI. |
| Լեզու: | անգլերեն |
| Հրապարակվել է: |
2023
|
| Խորագրեր: | |
| Առցանց հասանելիություն: | http://earchive.tpu.ru/handle/11683/74886 https://doi.org/10.3390/biomedicines11030714 |
| Ձևաչափ: | Էլեկտրոնային Գրքի գլուխ |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=669249 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 669249 | ||
| 005 | 20250213134311.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\40489 | ||
| 035 | |a RU\TPU\network\40172 | ||
| 090 | |a 669249 | ||
| 100 | |a 20230310d2023 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a CH | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Cardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction |f M. B. Plotnikov, G. A. Chernysheva, V. I. Smol'yakova [et al.] | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: 92 tit.] | ||
| 330 | |a Activation of c-Jun N-terminal kinases (JNKs) is involved in myocardial injury, left ventricular remodeling (LV), and heart failure (HF) after myocardial infarction (MI). The aim of this research was to evaluate the effects of a selective JNK inhibitor, 11H-indeno [1,2-b]quinoxalin-11-one oxime (IQ-1), on myocardial injury and acute myocardial ischemia/reperfusion (I/R) in adult male Wistar rats. Intraperitoneal administration of IQ-1 (25 mg/kg daily for 5 days) resulted in a significant decrease in myocardial infarct size on day 5 after MI. On day 60 after MI, a significant (2.6-fold) decrease in LV scar size, a 2.2-fold decrease in the size of the LV cavity, a 2.9-fold decrease in the area of mature connective tissue, and a 1.7-fold decrease in connective tissue in the interventricular septum were observed compared with the control group. The improved contractile function of the heart resulted in a significant (33%) increase in stroke size, a 40% increase in cardiac output, a 12% increase in LV systolic pressure, a 28% increase in the LV maximum rate of pressure rise, a 45% increase in the LV maximum rate of pressure drop, a 29% increase in the contractility index, a 14% increase in aortic pressure, a 2.7-fold decrease in LV end-diastolic pressure, and a 4.2-fold decrease in LV minimum pressure. We conclude that IQ-1 has cardioprotective activity and reduces the severity of HF after MI. | ||
| 461 | |t Biomedicines | ||
| 463 | |t Vol. 11, iss. 3 |v [714, 15 p.] |d 2023 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a cardioprotective activity | |
| 610 | 1 | |a c-Jun N-terminal kinase inhibitor | |
| 610 | 1 | |a 11H-indeno[1,2-b]quinoxalin-11-one oxime | |
| 610 | 1 | |a heart failure | |
| 610 | 1 | |a infarct size | |
| 610 | 1 | |a myocardial infarction | |
| 610 | 1 | |a ischemia/reperfusion | |
| 610 | 1 | |a сердечная недостаточность | |
| 610 | 1 | |a инфаркт миокарда | |
| 610 | 1 | |a ишемия | |
| 610 | 1 | |a реперфузия | |
| 701 | 1 | |a Plotnikov |b M. B. |g Mark | |
| 701 | 1 | |a Chernysheva |b G. A. |g Galina | |
| 701 | 1 | |a Smol'yakova |b V. I. |g Vera | |
| 701 | 1 | |a Aliev |b O. I. |g Oleg | |
| 701 | 1 | |a Fomina |b T. I. |g Tatyana | |
| 701 | 1 | |a Sandrikina |b L. A. |g Lyubov | |
| 701 | 1 | |a Sukhodolo |b I. V. |g Irina | |
| 701 | 1 | |a Ivanova |b V. V. |g Vera | |
| 701 | 1 | |a Osipenko |b A. N. |g Anton | |
| 701 | 1 | |a Anfinogenova |b N. D. |g Nina | |
| 701 | 1 | |a Khlebnikov |b A. I. |c Chemist |c Professor of Tomsk Polytechnic University |f 1963- |g Andrey Ivanovich |3 (RuTPU)RU\TPU\pers\33927 |9 17500 | |
| 701 | 1 | |a Atochin |b D. N. |c neuroscientist |c The Head of the Laboratory of Tomsk Polytechnic University |f 1960- |g Dmitry Nikolaevich |3 (RuTPU)RU\TPU\pers\37514 | |
| 701 | 1 | |a Schepetkin (Shchepyotkin) |b I. A. |c doctor-biophysicist |c leading researcher of Tomsk Polytechnic University, candidate of medical science |f 1962- |g Igor Aleksandrovich |3 (RuTPU)RU\TPU\pers\37358 | |
| 701 | 1 | |a Quinn |b M. T. |g Mark | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет |b Инженерная школа новых производственных технологий |b Научно-образовательный центр Н. М. Кижнера |3 (RuTPU)RU\TPU\col\23556 |
| 801 | 0 | |a RU |b 63413507 |c 20230329 |g RCR | |
| 856 | 4 | |u http://earchive.tpu.ru/handle/11683/74886 | |
| 856 | 4 | |u https://doi.org/10.3390/biomedicines11030714 | |
| 942 | |c CF | ||